Randomised Phase I/II Trial in Order to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Neoadjuvant Low-Dose-Radiation Therapy in Primarily Resectable Pancreatic Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumoral activity
1 year
No
Peter E. Huber, Prof. PhD MD
Principal Investigator
German Cancer Research Centre and Clinic for Radiation Oncology of the University of Heidelberg
Germany: Federal Office for Radiation Protection
IMPACT2010
NCT01027221
November 2009
December 2012
Name | Location |
---|